Thelansis

Glycogen Storage Disease Type 1a (GSD1a) Market Outlook Thelansis’s “Glycogen Storage Disease Type 1a (GSD1a) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glycogen Storage Disease Type 1a (GSD1a) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will h...

Glycogen Storage Disease Type 1a (GSD1a) Market Outlook Thelansis’s “Glycogen Storage Disease Type 1a (GSD1a) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glycogen Storage Disease Type 1a (GSD1a) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Glycogen Storage Disease Type 1a (GSD1a) Overview Glycogen Storage Disease Type 1a (GSD1a) is a rare autosomal recessive metabolic disorder caused by deficiency of the enzyme glucose-6-phosphatase. This defect blocks the final step of glycogenolysis and gluconeogenesis, leading to accumulation of glycogen and fat in the liver and kidneys and to metabolic complications including profoun...